This is an ERS International Congress abstract. This article was presented at the 2022 ERS International Congress, in session “-”. 6MWD increases at Week 16 were observed in PAH patients taking TRE on both mono and dual background therapy.Ĭite this article as Eur Respir J 2022 60: Suppl. AEs were more common in the mono (58%) versus the dual (42%) therapy group.Ĭonclusions: The number of background therapies did not impact clinical efficacy of TRE as measured by change in 6MWD. Results: Median (IQR) change in 6MWD for mono (n = 192) and dual background therapy (n = 139) patients receiving TRE was +16 m (-8,47) and +14 m (-16,58), respectively, with no statistical difference between groups (p = 0.8538). Adverse events (AEs) were compared between TRE subgroups. Methods: A nonparametric ANCOVA was used to assess differences between TRE patients on mono and dual background therapy in 6MWD change from baseline to Week 16. Here, we combined data from FREEDOM-C and C2 to compare efficacy on 6MWD in PAH patients on mono or dual background therapy.

Background/Aim: FREEDOM-C and C2 evaluated the effect of oral treprostinil (TRE) on 6-minute walk distance (6MWD) change at Week 16 for pulmonary arterial hypertension (PAH) patients adding TRE to mono or dual background therapy (ERA and/or PDE-5i).

Add endnote to word